LifeMD vs. MEDVi: prices, fine print, and the honest verdict

Tirzepatide pricing

On tirzepatide, MEDVi is the cheaper program at $399 a month all-in versus LifeMD's $597 — a gap of $198 a month, $2,376 a year, at the 10 mg maintenance basis. LifeMD: $597 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, including the mandatory $149/mo membership. MEDVi: $399 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $249/mo (12-month plan). Prepaid terms reorder things: MEDVi at $249/mo (12-month plan) — paid up front, with the regulatory-era caveat that locked-in months deserve a read of the refund terms first.

Semaglutide pricing

On semaglutide, MEDVi wins at $299 versus $348 all-in — $49/mo apart. LifeMD: Semaglutide runs $348 a month all-in. MEDVi: Semaglutide runs $299 a month all-in at the standing rate ($179 on intro/plan terms).

Transparency

LifeMD: Third-party-reported (verified 2026-08-05); dispensing pharmacy not publicly named. MEDVi: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

LifeMD: program fee recurs monthly; program fee recurs until cancelled; $149/mo membership recurs until cancelled. MEDVi: 12-month plan for the lowest rate; 12-month plan applies to lowest rate.

The gap, compounded over time

A $198/month difference sounds decidable by coin flip until it's annualized: choosing LifeMD over MEDVi at the standing rates costs an extra one month, $198; six months, $1,188; a year, $2,376; two years of maintenance, $4,752. Only MEDVi publishes a prepaid tier ($249/mo effective), which undercuts even LifeMD's standing $597 by $4,176/year — flexibility versus committed savings, cleanly posed. Every figure is the all-in maintenance basis; the arithmetic reruns from the dataset.

The 24-month ledger

Zoom to the horizon that matters for a chronic-use drug — 24 months — and LifeMD bills $14,328 and MEDVi $9,576, a spread of $4,752 for the same molecule at the same 10 mg basis. If prepaid terms held across both years, MEDVi's $249 effective would total $5,976 — $3,600 under even the cheaper standing plan, with the standing caveat that two years of locked funds in this regulatory climate is a real bet, not a rounding choice. Reference rails for the same 24 months: $5,160 at the verified floor, $10,776 on brand Zepbound at maintenance, $8,376 on Wegovy flat.

Two ladders, side by side

The 2.5-to-10 mg climb is the honest stress test: LifeMD holds $597 on every rung (four-month titration: exactly $2,388); MEDVi holds $399 on every rung (four-month titration: exactly $1,596). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

Three buyers, two invoices

The month-one starter pays $597 at LifeMD versus $399 at MEDVi for the 2.5 mg rung — an early edge that holds once the ladder climbs. The settled 10 mg maintainer — the buyer our basis is built for — pays $4,788/year at MEDVi against $7,164 at the other: $2,376 of annual daylight for the same molecule and dose. The committed prepayer does best at MEDVi: $249/month effective, $2,988/year, funds up front, refund terms first.

The semaglutide board

MEDVi takes the semaglutide board too at $299 versus $348 all-in — a $49/month, $588/year spread. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. LifeMD's ranked figure is $597 ($448 medication + $149 mandatory membership); MEDVi's ranked figure is $399, with no membership to add. 2 · Maintenance basis. LifeMD is dose-flat, so its entry and 10 mg figures coincide; MEDVi is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. LifeMD: standing $597, no prepaid tier; MEDVi: standing $399, prepaid $249 effective (12-month plan) — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. LifeMD: third-party-reported, read 2026-08-05; MEDVi: source-verified, read 2026-08-05. 5 · Pharmacy weighed. LifeMD names no pharmacy; MEDVi names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

LifeMD: a mandatory $149/mo membership folded into our all-in figure; program fee recurs until cancelled; commitment: program fee recurs monthly. MEDVi: no membership — the medication figure is the billed figure; prepaid 12-month plan at $249/mo effective; 12-month plan applies to lowest rate; commitment: 12-month plan for the lowest rate. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

LifeMD carries third-party-reported pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. MEDVi carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Neither program locks the door: a LifeMD-to-MEDVi move is a new intake, a new prescription at the new pharmacy, and a written cancellation at the old shop — typically a one-to-two-week overlap if you time the last fill. What does not move with you: prepaid months, membership balances, and any dose paperwork, so re-state your current rung clearly at the new intake.

Refills, shipping, and the week-to-week reality

Past the pricing page, the operational facts are what a subscriber lives with: LifeMD: shipping included; consultation video visits included in program fee; video visit model. MEDVi: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick LifeMD if you want the insurance paperwork done for you. Pick MEDVi if the $198/month tirzepatide saving is the point; the semaglutide line is cheaper here; you'll prepay for the $249 effective rate; you refuse membership fees on principle. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

Two programs never exhaust the market — the nearest substitutes on the verified board are Eden at $408 (dose-scaled, $99 membership included); Remedy Meds at $399 (flat, no membership); Fridays at $359 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $600/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

On the numbers alone, MEDVi is the cheaper tirzepatide program by $198/mo and it doesn't trade that price for opacity ; LifeMD's case rests on insurance navigation. Both records, with dates and sources, live in the pricing database.